Prostaglandin E2 Receptors and COX Enzymes in Human Hepatocellular Carcinoma
- 26 February 2009
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1155 (1) , 300-308
Abstract
The aim of this study was to investigate the expression of prostaglandin E(2) receptors (EP(1-4)), cyclooxygenase-1 (COX-1), and COX-2 in nontumor and tumor human liver tissues, and also to evaluate the antitumor activity of selective EP(1) receptor antagonist used alone or in combination with COX-1 and COX-2 selective inhibitors. Semiquantitative PCR analyses revealed that EP(1-4), COX-1, and COX-2 mRNA expression was detected in nearly all the tissue samples assayed, although with a high variability between nontumor and tumor tissues. In vitro EP(1) receptor antagonist inhibited anchorage-independent cell growth and reduced the viability of hepatocellular carcinoma (HCC) cells in a dose-dependent manner. Moreover, treatment with the combination of EP(1) receptor antagonist and COX inhibitors produced a significantly greater cell growth inhibition than the single agent alone. These findings suggest that the EP(1) receptor may represent an important target for HCC treatment, and in addition they could provide preclinical support for a combined chemotherapeutic approach with EP(1) antagonists and COX inhibitors in the treatment of liver cancer.Keywords
This publication has 17 references indexed in Scilit:
- Differential expression of E‐prostanoid receptors in human hepatocellular carcinomaInternational Journal of Cancer, 2007
- G-protein-coupled receptors and cancerNature Reviews Cancer, 2007
- A prostaglandin E2 receptor subtype EP1-selective antagonist, ONO-8711, suppresses 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesisCarcinogenesis, 2006
- Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cellsJournal of Cellular Physiology, 2005
- Suppression of azoxymethane‐induced colon cancer development in rats by a prostaglandin E receptor EP1‐selective antagonistCancer Science, 2005
- Induction of Apoptosis and Inhibition of Cell Growth in Human Hepatocellular Carcinoma Cells by COX‐2 InhibitorsAnnals of the New York Academy of Sciences, 2004
- Downregulation of prostaglandin E receptor subtype EP 3 during colon cancer developmentGut, 2004
- Prostanoid receptor signaling relevant to tumor growth and angiogenesisTrends in Pharmacological Sciences, 2003
- Phosphorylation of Glycogen Synthase Kinase-3 and Stimulation of T-cell Factor Signaling following Activation of EP2 and EP4 Prostanoid Receptors by Prostaglandin E2Journal of Biological Chemistry, 2002
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000